Modafinil
/ Wakefulness-promoting agent (small molecule, sulfinyl class)ALIAS · Provigil (trade) · Alertec (trade — Canada) · Modiodal (trade — France/Japan) · 2-(diphenylmethylsulfinyl)acetamide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 1. FDA-approved 1998 for narcolepsy, with subsequent approvals for shift-work sleep disorder (2004) and as adjunct for residual sleepiness in obstructive sleep apnea. Multiple Phase 3 RCTs; DEA Schedule IV controlled substance.
Modafinil is a wakefulness-promoting agent whose precise mechanism remains incompletely characterised. The best-supported molecular action is weak inhibition of the dopamine transporter (DAT), elevating extracellular dopamine in the nucleus accumbens and prefrontal cortex; secondary effects on histaminergic, orexinergic, and noradrenergic systems have also been reported.
Unlike classical stimulants, modafinil does not produce robust monoamine release and shows a more selective wake-promoting profile with reduced peripheral sympathomimetic activity. The compound is structurally distinct from amphetamines and methylphenidate and was originally developed in France in the 1970s as the (R)-enantiomer is the more pharmacologically active form (marketed separately as armodafinil).
Tier 1. Multiple Phase 3 RCTs supported FDA approval for narcolepsy (1998), shift-work sleep disorder (2004), and OSA-associated residual sleepiness. Off-label investigation in sleep-deprivation cognition (Wesensten 2002) and in shift-work populations (Czeisler 2005 NEJM SHIFT-MOD trial) has generated additional human data on alertness and cognitive performance.
Common adverse events include headache, nausea, anxiety, and insomnia. Rare but serious cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) prompted an FDA warning in 2007. Modafinil is a CYP3A4 inducer and can reduce efficacy of hormonal contraceptives. DEA Schedule IV reflects observed abuse liability lower than amphetamines but non-zero.
Regulatory status
- FDA status:
- FDA-approved
- Compounding:
- Not eligible for compounding (approved, not in shortage)
The wakefulness mechanism is mechanistically debated — the dopaminergic contribution is well-supported but the broader 'cognitive enhancement in non-sleep-deprived' literature is heterogeneous and confounded by publication bias. Off-label use in healthy adults for cognitive enhancement substantially exceeds approved indications and has limited controlled data on chronic use, dependence, or effects on developing brains.